Good morning and greetings from Pharmalot’s New York bureau. Jason Mast here filling in. Today, I’m still listening to the music recommendation from Pharmalittle’s Friday dispatch — I’ll admit that until today my Traffic knowledge started and ended with a certain saxophone-flecked 1971 hit — and trying to celebrate the coming autumn, rather than mourn the end of summer. Here’s today news:
Bayer, Takeda, and CSL Behring — alongside several mid-sized drugmakers — are part of the new drug pricing deals the White House is expected to announce Monday, the Financial Times reports. The agreements are the latest in a slate of deals the Trump administration has signed with major drugmakers, generally extracting drug pricing concessions in exchange for salary relief — although it’s been unclear how meaningful the drug pricing concessions are.
The FDA approved Takeda and Protagonist’s drug for a slow-growing cancer, STAT tells us. The weekly injection, called Mimrylo, is approved to treat polycythemia vera, a cancer marked by the overproduction of red blood cells. The cells thicken a patient’s blood, putting them at higher risk for life-threatening heart attacks, strokes, and blood clots. The companies did not disclose a price.
